1 Day NVO 1.88% DJIA 0.68% S&P 500 -0.03% Health Care/Life Sciences 2.54% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity and diabetes, saying the drug is too complex to be made safely ...

Novo's new obesity therapy Wegovy is significantly expanding the obesity treatment market given its strong efficacy and is poised to remain a key drug in the market until patent expiration in 2032.

With Novo Holdings’ $16.5 billion buyout of Catalent being reviewed by regulators, what work the contract drug manufacturer may or may not be performing for Eli Lilly remains a point of contention.

The table below shows the extended goals stats for Fanático de Campo Largo and Novo Mundo. The percentage numbers show the games with specific stats compared to the total games played by each team.

The table below shows the extended goals stats for NK Borac Novo Selo and PPG Rujevac. The percentage numbers show the games with specific stats compared to the total games played by each team. First ...

Tennessee football finished 4-0 in its four-game homestand with a 33-14 victory against Mississippi State on Saturday night at Neyland Stadium. It may have been a costly victory for the Vols (8-1 ...

Liverpool opened a five-point lead at the top of the Premier League as breakaway goals by Darwin Nunez and Mohamed Salah sealed a 2-0 win at home to Aston Villa on Saturday. Manchester City's ...

Jackson State football began Saturday’s game slow offensively and struggled to score against winless Mississippi Valley State. The defense couldn’t find a rhythm to stop MVSU's fast-tempo ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...